Vpliv biokemičnih in kliničnih značilnosti na pojav peritonitisa, pri pacientih zdravljenih s peritonealno dializo

Koroša, Ana

| | SLO | ENG | Cookies and privacy

Bigger font | Smaller font

First page > Show document

Show document

Title:	Vpliv biokemičnih in kliničnih značilnosti na pojav peritonitisa, pri pacientih zdravljenih s peritonealno dializo
Authors:	ID Koroša, Ana (Author) ID Ekart, Robert (Mentor) More about this mentor... ID Lorber, Mateja (Comentor)
Files:	MAG_Korosa_Ana_2017.pdf (958,26 KB) MD5: 249686D519DEEE0DED65FD3A178D948C PID: 20.500.12556/dkum/6356c0f2-551c-4373-8cda-97ee5de88cea
Language:	Slovenian
Work type:	Master's thesis/paper
Typology:	2.09 - Master's Thesis
Organization:	FZV - Faculty of Health Sciences
Abstract:	Uvod: Pri pacientih s končno ledvično odpovedjo, ki se zdravijo s peritonealno dializo (PD), lahko številni dejavniki prispevajo k nastanku peritonitisa. Namen naše raziskave je bil pri pacientih, zdravljenih s PD, analizirati povezavo med različnimi kliničnimi dejavniki in biokemičnimi vrednostmi ter pojavom peritonitisa. Metode: V raziskavo smo vključili 53 pacientov, starih od 15 do 67 let, ki so začeli zdravljenje s PD na Oddelku za dializo Univerzitetnega kliničnega centra Maribor v obdobju od maja 1998 do novembra 2016. Analizirali smo biokemične vrednosti in klinične dejavnike pacientov, zdravljenih s PD, ob pričetku zdravljenja s PD ter nato ob pojavu prvega peritonitisa oziroma ob koncu opazovanega obdobja. V opazovanem obdobju 1615 mesecev (1–123,7 meseca, povprečno 30,5±30,9 meseca), smo pri 15 pacientih (28,3 %) diagnosticirali peritonitis. Rezultati: Pacienti, ki so preboleli peritonitis, so imeli v primerjavi s pacienti brez prebolelega peritonitisa ob pričetku zdravljenja s PD višjo koncentracijo serumskega fosfata (U = 155,00, p = 0,010). Povprečni čas verjetnosti pojava prvega peritonitisa pri vseh pacientih je bil 77,4 meseca (95% IZ [59,7; 95]). Pacienti z normalnim serumskim fosfatom ob pričetku zdravljenja s PD so imeli povprečen čas preživetja, do pojava peritonitisa, 110 mesecev (95% IZ [92,1; 127,9]), pacienti z visokim serumskim fosfatom pa so imeli povprečen čas preživetja do pojava peritonitisa, 67,3 mesecev (95% IZ [10; 47,7]). Razprava: Rezultati naše raziskave kažejo na pomemben vpliv serumskega fosfata na pojav peritonitisa ob pričetku zdravljenja s PD. Ta ugotovitev je lahko v pomoč pri prepoznavanju pacientov, ki zdravljenje s PD pričnejo z visokim nivojem serumskega fosfata in imajo zato višje tveganje za nastanek peritonitisa.
Keywords:	končna odpoved ledvic, preddializno izobraževanje pacientov, peritonealna dializa, peritonitis, serumski fosfat.
Place of publishing:	Maribor
Publisher:	[A. Koroša]
Year of publishing:	2017
PID:	20.500.12556/DKUM-69097
UDC:	616.61-008.6
COBISS.SI-ID:	2380964
NUK URN:	URN:SI:UM:DK:GYSRGT3O
Publication date in DKUM:	10.01.2018
Views:	1642
Downloads:	182
Metadata:
Categories:	FZV
:	Copy citation

Average score:	(0 votes)
Your score:	Voting is allowed only for logged in users.
Share:

Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Licences

License:	CC BY 4.0, Creative Commons Attribution 4.0 International

Link:	http://creativecommons.org/licenses/by/4.0/
Description:	This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:	29.11.2017

Secondary language

Language:	English
Title:	The influence of biochemical and clinical characteristics to peritonitis in peritoneal dialysis patients
Abstract:	Introduction: Many factors can contribute to the development of peritonitis. The purpose of our research was to analyse the link between different clinical factors and biochemical values and peritonitis in patients treated with peritoneal dialysis (PD). Methods: The study included 53 patients, aged 15 to 67 years who have started treatment with PD at the Department of Dialysis UKC Maribor in the period from May 1998 to November 2016. We analysed the biochemical values and clinical characteristics of patients treated with PD at the beginning of treatment and their association with the occurrence of peritonitis. In the period of 1.615 months (1–123.7 months, an average of 30.5 ± 30.9 months), 15 patients (28.3%) developed peritonitis. Results: Patients with peritonitis had at the start of PD treatment higher levels of serum phosphate (U = 155.00, p = 0.010) than patients without peritonitis. The average time the likelihood of first peritonitis in all patients was 77.4 months (95% CI [59.7, 95]). In patients with normal serum phosphorus at the start of PD treatment was survival time to the first episode of peritonitis 110 months (95% CI [92.1, 127.9]), in patients with higher serum phosphate was this survival time 67.3 months (95% CI [10, 47.7]). Discussion and conclusions: The results of our study demonstrated a significant effect of serum phosphate on the occurrence of peritonitis. These findings can help identify patients who start PD treatment with higher serum phosphate which have a higher risk of peritonitis.
Keywords:	end stage renal disease, predialysis education of patients, peritoneal dialysis, peritonitis, phosphorus.

Comments

Leave comment

You must log in to leave a comment.

Comments (0)

0 - 0 / 0

There are no comments!

Back